Supplementary Figure 4 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer | Synapse
October 7, 2024Open Access
Supplementary Figure 4 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Supplemental Figure 4 shows the relationship between Immune Signature score by Patient Cohort and UROMOL subtype.